Literature DB >> 23824265

Primary care of patients with high cardiovascular risk : Blood pressure, lipid and diabetic target levels and their achievement in Hungary.

Endre Szigethy1, Zoltán Jancsó, Csaba Móczár, István Ilyés, Eszter Kovács, László Róbert Kolozsvári, Imre Rurik.   

Abstract

Cardiovascular diseases are responsible for the majority of premature deaths in Hungary as well. Most of them could be prevented with healthy lifestyle of patients and adequate drug prescription of primary care physicians. Earlier European surveys found wide differences between the practices and achievements of different countries in this field. The study was based on and designed according to the framework of previous European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) studies and aimed presenting Hungarian results and comparing with the achievements of other countries and previous Hungarian surveys. Among rural and urban settings, 679 patients under continuous care (236 diabetics, 218 with dyslipidaemia, and 225 with hypertension) were consecutively selected by 20 experienced general practitioners. The mean age of patients was 60.3 years (men) and 64.0 years (women). Among diabetics, less than 7 % of glycated hemoglobin (HbA1c) values were found in 42.5 % patients, while only 11.4 % patients had fasting plasma sugar less than 6.0 mmol/L. Of the patients treated for dyslipidaemia, the target level of triglyceride was reached by 40.6 %, recommended total cholesterol by 14.2 % and the HDL-cholesterol by 71.8 %. The therapeutic control of total and HDL-cholesterol was better in men, although women had better triglyceride values. The achievement among patients with hypertension was 42.0 %. Significantly higher blood pressure was measured by patients who were treated with not recommended combinations of antihypertensive medication. A remarkable improvement could be observed in Hungary in the field of secondary prevention. It was greater among patients with hypertension and dyslipidaemia and smaller in diabetes care. Compared to the results of published European surveys, Hungary occupies a good position, but further improvement is still required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824265     DOI: 10.1007/s00508-013-0379-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  40 in total

1.  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.

Authors: 
Journal:  Eur Heart J       Date:  1997-10       Impact factor: 29.983

2.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Control of cardiovascular risk factors in patients with type 2 diabetes and hypertension in a French national study (Phenomen).

Authors:  G Prévost; T M Phan; C Mounier-Vehier; P Fontaine
Journal:  Diabetes Metab       Date:  2005-11       Impact factor: 6.041

5.  [Continuing care of patients with cardiovascular risk in general practice: patients with hypertension and their care].

Authors:  Zoltán Jancsó; Hajnalka Márton; Attila Simay; Eszter Kovács; István Iléys
Journal:  Orv Hetil       Date:  2006-02-26       Impact factor: 0.540

6.  Treatment of hypertension in Finnish general practice seems unsatisfactory despite evidence-based guidelines.

Authors:  Juha Varis; Heljä Savola; Risto Vesalainen; Ilkka Kantola
Journal:  Blood Press       Date:  2009       Impact factor: 2.835

7.  Management of dyslipidemia in primary care.

Authors:  Turky Alzahrani; Saida Marrat; Aamir Haider
Journal:  Can J Cardiol       Date:  2003-12       Impact factor: 5.223

8.  [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].

Authors:  Zoltán Jancsó; Zsuzsa Varga; Attila Simay; István Ilyés
Journal:  Orv Hetil       Date:  2005-12-25       Impact factor: 0.540

9.  Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: risk factors, treatment and target level attainment.

Authors:  H Völler; R Reibis; D Pittrow; C Jannowitz; K Wegscheider; B Karmann; K Bestehorn
Journal:  Curr Med Res Opin       Date:  2009-04       Impact factor: 2.580

10.  ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice].

Authors:  P Ott; I Benke; J Stelzer; C Köhler; M Hanefeld
Journal:  Dtsch Med Wochenschr       Date:  2009-02-05       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.